[go: up one dir, main page]

EP1221974A2 - Porteurs magnetiques cibles composes de fer et de matieres poreuses pour l'administration ciblee d'agents biologiquement actifs - Google Patents

Porteurs magnetiques cibles composes de fer et de matieres poreuses pour l'administration ciblee d'agents biologiquement actifs

Info

Publication number
EP1221974A2
EP1221974A2 EP00972209A EP00972209A EP1221974A2 EP 1221974 A2 EP1221974 A2 EP 1221974A2 EP 00972209 A EP00972209 A EP 00972209A EP 00972209 A EP00972209 A EP 00972209A EP 1221974 A2 EP1221974 A2 EP 1221974A2
Authority
EP
European Patent Office
Prior art keywords
particles
iron
ceramic
biologically active
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00972209A
Other languages
German (de)
English (en)
Inventor
Scott Raymond Rudge
Terri Lynn Kurtz
Gilles Hugues Tapolsky
Yuhua Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ONKOR PHARMACEUTICALS Inc
Original Assignee
FeRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FeRx Inc filed Critical FeRx Inc
Publication of EP1221974A2 publication Critical patent/EP1221974A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to compositions, methods of manufacture and methods for delivery of biocompatible particles to a selected location in a body and, more particularly, relates to particles capable of carrying biologically active compounds and which provide for targeted magnetic transport ofthe particles and their maintenance in a predetermined place as a localized therapeutic treatment for disease, diagnostic aid, or bifunctional composition capable of acting as both a diagnostic and therapeutic agent.
  • Magnetic carrier compositions for treating various disorders have been previously suggested and utilized, and include compositions which are guided or controlled in a body in response to an externally applied magnetic field. (See Lieberman et al., U.S. Patent 4,849,209; Schroder et al., U.S. Patent 4,501,726; Chang, U.S. Patent 4,652,257; and Mirell, U.S. Patent 4,690,130).
  • composition deliverable by way of intravascular injection, includes microspheres made of a ferromagnetic component covered with a biocompatible polymer (albumin, gelatin, and polysaccharides) which also contains a drug (Driscol, CF. et al., Prog.
  • albumin microspheres up to 3.0 ⁇ m in size containing a magnetic material (magnetite Fe 3 0 ) and the anti-tumoral antibiotic doxorubicin (Widder, K. et al, J. Pharm. Sci., 68:79-82, 1979).
  • Such microspheres are produced through thermal and/or chemical denaturation of albumin in an emulsion (water-in-oil), with the disperse phase containing a magnetite suspension in a medicinal solution.
  • emulsion water-in-oil
  • a similar technique has been used to produce magnetically controlled, or guided, microcapsules covered with ethylcellulose containing the antibiotic mitomycin-C (Fujimoto, S.
  • Magnetically controlled liposomes 200 nm to 800 nm in size, capable of carrying preparations that can dissolve atherosclerotic formations are also known. This method is based upon the ability of phospholipids to create closed membrane structures in the presence of water (Gregoriadis G., Ryman B.E., Biochem. J., 124:58, 1971).
  • compositions have not always proven practical and/or effective. Often, there is ineffective drug concentration delivered to the targeted site. Many of the compositions lack adequate transport capacity, exhibit weak magnetic susceptibility, and/or require extremely high flux density magnetic fields for their control. In some cases, there is no real localization ofthe particles enabling a precise local therapy. Other shortcomings include non-specific binding and toxicity to untargeted organs for compositions incorporating antibodies and peptides, and drug diffusion outside ofthe desired site for intra- tumoral injection based technologies. Some compositions are difficult to manufacture or prepare consistently, sterilize, and store without changing their designated properties.
  • One suggested composition comprises ferrocarbon particles for use as magnetically susceptible material for magnetically controlled compositions. These particles have a major dimension (i.e., largest diameter) of about 0.2 ⁇ m to about 5.0 ⁇ m (and preferably from 0.5 ⁇ m to 5.0 ⁇ m) and contain from about 1.0% to about 95.0% (by mass) of carbon, with the carbon strongly connected to iron.
  • the particles are obtained by jointly deforming (i.e., milling) a mixture of iron and carbon powders. See U.S. Patents 5,549,915; 5,651,989;
  • Iron-ceramic composite particles show great versatility to bind to various drugs that adsorb at the particle surface for easy incorporation of the active agent Additionally, lron- ceramic particles utilize metallic iron with a higher magnetic susceptibility than iron oxides, thereby facilitating and expediting mobility to the treatment site Furthermore, the biocompatibility properties of ceramics are well known
  • the aim of this invention is to improve some parameters of magnetically controlled compositions used for the targeted transport of a biologically active substance, including enabling use of natural bone constituents in the carrier particle, expanding the categones of therapeutics and diagnostics for which this technology can be used, increasing relative absorption capacity and magnetic susceptibility by, for example, providing a large number of ionic groups that enable bin ⁇ mg of compounds by ionic interactions, improving biocompatibility ana biodegradability, intensifying diagnostic and therapeutic effect, simplifying the technology of manufacturing the magnetically controlled composition, and ensunng its guaranteed long-term storage capabilities without changing the desired charactenstics
  • suitable composite, iron-ceramic particles as a magnetically susceptible matenal for a magnetically controlled composition
  • the particles are disk and sphencally shaped, approximately 0 1 to 10 0 ⁇ m diameter, and contain 1 0% to 95 0% ceramic (or a denvatized ceramic) and 5 0% to 99 0% iron, by iron They are obtained by jointly deforming (i e , milling) a mixture of iron and ceramic powders
  • Adsorption occurs on the surface, or modified surface, of the particle so the drug is readily available and capable of incorporation at the treatment site
  • the powders are combined in a planetary ball, or attntion mill with a solvent (e g ethanol)
  • a solvent e g ethanol
  • the resulting composite powder is then sieved or magnetically separated to obtain the desired fraction of product, and correspondingly, the desired magnetic susceptibility
  • the biologically active agent or diagnostic aid is adsorbed to or deposited on to the composite and administered to the patient m a suspension of the composite in a stenle diluent
  • the methods of use include methods for localized in vivo diagnosis or treatment of disease providing a magnetically responsive iron-ceramic earner having adsorbed thereon a biologically active substance selected for its efficacy m diagnosing or treating the disease, and injecting the earner into the body of a patient
  • the earner is injected b> inserting delivery means into an artery to within a short distance from a body site to be treated and at a branch or branches (preferably the most immediate) to a network of artenes carrying blood to the site
  • the earner is injected through the delivery means into the blood vessel.
  • a magnetic field is established extenor to the body and adjacent to the site with sufficient field strength to guide a substantial quantity ofthe injected earner to, and retain the substantial quantity of the earner at, the site
  • the magnetic field is of sufficient strength to draw the earner into the soft tissue at the site adjacent to the network of vessels, thus avoiding substantial embohzation of any of the larger vessels by the carrier particles. See, for example, U.S. Provisional Application Ser. No. 60/160,293, which is incorporated herein by reference.
  • It is another object of this invention to provide a magnetically responsive composition comprising particles approximately 0.1 to 10.0 ⁇ m in diameter, each iron-ceramic particle containing 1.0% to 95.0% ceramic (or a ceramic derivative) and 5.0% to 99.0% iron, by mass.
  • It is still another object of this invention to provide a composition utilized for localized in vivo diagnosis or treatment of disease including a carrier with composite iron- ceramic particles approximately 0.1 to 10.0 ⁇ m in diameter, each iron-ceramic particle containing 1.0% to 95.0% ceramic (or a ceramic derivative) and 5.0% to 99.0% iron, by mass, and having adsorbed thereon one or more optional biologically active substances selected for efficacy in diagnosing and/or treating a particular disease.
  • FIG 1 is a magnified photograph (X1000) of composite iron-silica particles
  • FIG. 2 is a magnified photograph (X3000) of composite iron-silica particles.
  • FIG. 3 is a flow diagram ofthe production process of this invention.
  • FIG. 4 is a Doxorubicm binding curve for an iron-silica gel composite
  • FIG. 5 is Doxorubicm binding curve for an iron-C18 composite
  • FIG. 6 is a Scanning Electron Microscopy photograph showing the morphology of iron-hydroxyapatite particles.
  • FIG. 7 is the same frame as m FIG. 6, with momtonng of backscatter to show iron in white and hydroxyapatite in black
  • FIG 8 is the spectra of the particle shown in FIG 6 confirming that the white spots are composed of iron.
  • FIG. 9 is the spectra ofthe particle shown in FIG. 6 confirming that the black spots are composed of hydroxyapatite.
  • FIG. 10 is particle size analysis of hydroxyapatite particles using light scattenng technique.
  • FIG.l 1 is a magnetic susceptibility curve of an iron-hydroxyapatite microparticle using magnetometer technique.
  • FIG. 12 is a Langmuir isotherm plot for iron-hydroxyapatite.
  • FIG. 13 is a Langmuir isotherm plot for hydroxyapatite (no iron)
  • FIG. 14 is a doxorubicm desorption profile for iron-hydroxyapatite.
  • FIG. 15 shows labeling of iron-hydroxy apatite particles with Indium 1 1 1 by direct incubation and stability in different media.
  • FIG. 16 shows labeling of iron-hydroxyapatite particles with Indium 111/oxyqumoline and stability in different media.
  • the invention is a composite particle compnsed of 1 0% to 95 0% a ceramic ( or ceramic denvative) and 5 0% to 99 0% iron, by mass With compositions having less than 1 0% ceramic, the binding capacity of a particle is decreased to the point of being largely ineffective for carrying biologically active substances With compositions of greater than
  • the magnetic susceptibility is generally reduced beyond an effective level for targeting biologically active substances in vivo
  • the particles are disk and sphencally shaped, approximately 0 1 to 10 0 ⁇ m in diameter
  • ceramic means a natural or synthetic porous, adsorptive matenal It is usually, but not necessanly an oxide or mixed oxide, wherein the oxide is metallic or non- metallic It is usually, but not necessanly inorganic It is usually, but not necessanly without a crystalline structure
  • synthetic ceramic matenals include, but are not limited to t ⁇ calcium phosphate, hydroxyapatite, aluminum hydroxide, aluminum oxide, aluminum calcium phosphate, dicalcium phosphate dihydrate, tetracalcium phosphate, macroporous tnphasic calcium phosphate, calcium carbonates, hematite, bone meal, apatite wollastonite glass ceramics and other ceramic or glass matnces
  • polymers that have a degree of crystallmity that will support pores and adsorption Examples of such polymers mclude, but are not limited to polyethylenes, polypropylenes, and polystyrenes Appropnate
  • silica and silica denvatives including, but not limited to octadecycl silane [C ⁇ 8 ], octyl silane [C 8 ], hexyl silane [Co], phenyl silane [C 6 ], butyl silane [C 4 ], aminopropylsilane [NH 3 C 3 ], cyano nitnle silane [CN], tnmethylsilane [Ci], sulfoxyl propyl silane [SO 4 C J, dimethylsilane [Ci], acidic cation- exchange coating [SCX .
  • silica and silica denvatives including, but not limited to octadecycl silane [C ⁇ 8 ], octyl silane [C 8 ], hexyl silane [Co], phenyl silane [C 6 ], butyl silane [C 4 ], aminopropylsilane [NH 3 C 3 ], cyano nitnle si
  • SAX basic quaternary ammonium anion exchange coating
  • dihydroxypropyl silane [diol] dihydroxypropyl silane
  • silicas are useful for forming the composites of the invention.
  • Bonded phase coverage calculated as per Sander, L.C., and Wise, S.A., Anal. Chem., 56: 504- 510, 1984. Material characterisncs obtained from literature published by the material manufacturer or an authorized representative thereof.
  • the powders are mixed in a planetary ball, or attntion mill in the presence of a ⁇ qui ⁇ for example, ethanol, to inhibit oxidation of the iron
  • the liquid may also serve as a lubncant dunng the milling of the iron and ceramic powder, to produce the appropnate particle size distribution It also may reduce compacting of the ceramic dunng processing As a result, the porosity of the ceramic deposits in the composition is maintained so as to maximize adsorption capacity ofthe particles
  • the mixture is put into a standard laboratory planetary ball, or attntion mill of the type used in powder metallurgy
  • the mill holds canisters containing the iron and ceramic powders, ethanol, and metal or metal alloy balls of vanous diameters
  • the mill can have 6 mm diameter balls composed of case hardened metal carbide
  • the mill is run between 2 and 14 hours at speeds of 100 ⁇ m to 1000 ⁇ m It is believed that mill speeds over 1000 ⁇ m could create an undesirable quantity of overly small particles Approp ⁇ ate liquids and milling conditions are easily determined by any person having ordinary skill m the art.
  • the particles are removed from the mill and separated from the grinding balls, for example, by a strainer
  • the particles may be re-suspended in ethanol and homogenized to separate the particles from one another
  • the ethanol is removed, for example, by rotary evaporation, followed by acuum drying Any suitable drying technique may be employed, for example, in a vacuum oven (purging )
  • Particles should be handled so as to protect against oxidation of the iron, for example, a nitrogen environment.
  • the resulting dned powder may then be sieved or magnetically separated to obtain the desired fraction of product providing the desired magnetic susceptibility and therapeutic or diagnostic binding capacity
  • the product is then packaged into dosage units in a nitrogen- purged glove box and terminally ste ⁇ hzed
  • Any suitable stenhzation technique may be employed
  • the iron-ceramic particles may be sten zed using gamma irradiation and the aqueous solution of excipients may be stenhzed by autoclave
  • biologically active agent or agents When ready for use, the biologically active agent or agents are adsorbed to or precipitated onto the composite
  • the composite, with the active agent adsorbed, is administered to the patient m a suspension of the composite in a ste ⁇ le diluent
  • the iron-ceramic Darticies are useful as a earner for dehvenng one or more a ⁇ sorbe ⁇ biologically active substances to specific body sites under control of an external magnetic field
  • biologically active substance includes substances useful for in vivo medical diagnosis and/or treatment Biologically active substances include, but are not limited to, antineoplastics, blood products, biological response modifiers, anti-fungals, antibiotics, hormones, vitamins, proteins, peptides, enzymes, dyes, anti-allergies, anti-coagulants, circulatory agents, metabolic potentiators, antituberculars, antivirals, antianginals, anti-inflammatones, antiprotozoans, antirheumatics, narcotics, opiates,
  • Types of genetic matenal may include, for example, genes earned on expression vectors, such as plasmids. phagemids, cosmids, yeast artificial chromosomes, and defective (helper) viruses, antisense nucleic acids, both single and double stranded RNA and DNA and analogs thereof Also included are proteins, peptides and other molecules formed by the expression of genetic matenal
  • the type of detection instrument available is a ma j or factor in selecting a given radioisotope
  • the radioisotope chosen must have a type of decav that is detectable for a given type of instrument Generally, gamma radiation is required Still another important factor in selecting a radioisotope is that the half-life be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that deletenous radiation with respect to the host is minimized.
  • Radioisotopes which may be employed include, but are not limited to 99m Tc, l 42 Pr, l 61 Tb, ' S6 Re, and l 88 Re Additionally, typical examples of other diagnostically useful compounds are metallic ions including, but not limited to ' "in.
  • paramagnetic elements that are particularly useful in magnetic resonance imaging and electron spin resonance techniques include, but are not limited to ⁇ Gd, "Mn, 162 Dy, i2 Cr, and 56 Fe It is also note ⁇ tnat ra ⁇ ioisotopes are also useful m radiation therapy tecnmques Generally, alpha and beta radiation is considere ⁇ useful for therapy Examples of therapeutic compounds mclude, but are not limited to 2 P, 186 Re, 188 Re, l 23 I 12i I, 90 Y, l 66 Ho, " 3 Sm, , 42 Pr, 143 Pr, 149 Tb, 16, Tb, ⁇ ⁇ In, 77 Br, 212 B ⁇ , 213 B ⁇ , 223 Ra, 210 Po, , 9; Pt, 19im Pt, 2 ⁇ Fm, , 6i Dy, 109 Pd, 121 Sn, 12 / Te,
  • Advantages over current iron-carbon composite products include surface binding versatility, as well as biocompatibility and biodegradation properties of ceramics that are relatively well known
  • the amount of any aqueous soluble biologically active substance adsorbed can be increased by increasing the proportion of ceramic in the particles up to a maximum of about 50% by mass of the composite particles without loss of utility of the particles in the therapeutic treatment regimens desc ⁇ bed in this application
  • an increase the amount of adsorbed biologically active substance is approximately linear with the increase in ceramic content
  • the susceptibility, or responsiveness, of composite particles to a magnetic field decreases, and thus conditions for their control in the body worsen (although adso ⁇ tion capacity increases) Therefore, it is necessary to achieve a balance in the iron ceramic ratio to obtain improved therapeutic or diagnostic results
  • a larger dose of particles can be administered to the patient, but the particles cannot be made more magnetic by increasing the dose Appropnate ratios may be determined by any person having average skill m the art.
  • the useful range of iron ceramic ratio for particles intended for use in in vivo therapeutic treatments as descnbed in the application is, as a general rule, from about 99 1 to about 5 95 for example about 80 20 to about 60 40
  • the maximum amount of the biologically active substance that can be adsorbed in the composite lromceramic earner particles of any given concentration of ceramic will also differ depending upon the chemical nature of the biologically active substance, and, in some cases, the type of ceramic used in the composition Any person naving ordinary skill in the art will be able to determine the proper ratio for the desired application
  • the excipients may be prepared m dry form,and one or more dry excipients are packaged together with a unit dose of the earner particles
  • a wide vanety of excipients may be used, for example, to enhance adso ⁇ tion or deso ⁇ tion, or to increase solubility
  • the type and amount of appropnate dry excipients will be determined by one of skill in the art depending upon the chemical properties ofthe biologically active substance
  • the package or kit containing both the dry excipients and dry earner particles is formulated to be mixed with the contents of a vial containing a unit dose of the drug and sufficient amount of a biologically compatible aqueous solution, such as saline, as recommended by the drug manufacturer, to b ⁇ ng the drug to a pharmaceutically desirable concentration
  • the drug is allowed to be mixed with the contents of a vial containing a unit dose of the drug and sufficient amount of a biologically compatible aqueous solution, such as saline, as recommended by the drug manufacturer, to b
  • a liquid kit may be employed.
  • the earner particles are contained as one unit, for example, in a vial, while the aforementioned excipients are contained m another unit m the form of an aqueous solution
  • the ferroceramic particles are mixed with the contents of a vial containing a unit dose of the drug and sufficient amount of a biologically compatible aqueous solution, such as saline, as recommended by the drug manufacturer, to bnng the drug to a pharmaceutically desirable concentration.
  • the resulting particles having the biologically active substance adsorbed thereon are mixed with yet another unit containing the excipients in aqueous solution
  • a suitable stenhzation technique may be employed
  • the ferroceramic particles may be stenhzed using gamma irradiation and the aqueous solution of excipients may be stenhzed by autoclave Use of autoclave undesirably oxidizes the ferroceramic particles
  • the buffer used can have an impact on the overall binding Any person having ordinary skill m the art would oe able to determine the most appropnate buffer
  • a diagnostic or therapeutic amount of biologically active substance adsorbed to the earner particles will be determined by one skilled m the art as that amount necessary to effect diagnosis or treatment of a particular disease or condition, taking into account a vanety of factors such as the patient ' s weight, age, and general health, the diagnostic or therapeutic properties of the drug, and the nature and seventy of the disease
  • a number of considerations are involved m determining the size of earner particles to be used for any specific therapeutic situation
  • the choice of particle size is determined in part by technological constraints inherent in producing the particles under 0 2 ⁇ m in size
  • the magnetic control in blood flow and the carrying capacity is reduced
  • Relatively large particle sizes can tend to cause desirable or undesirable embohzation of blood vessels dunng injection either mechanically or by facilitating clot formation by physiological mechanisms
  • the dispersion may coagulate, which makes injections more difficult, and the rate at which biologically active substances desorb from the particles in the targeted pathological zones may decrease
  • the method (such as is descnbed below) of milling together a mixture of iron and ceramic powders produces an irregularly shaped form with a granular surface for the particles, and results in a particle population having an average major dimension of about 0 1 ⁇ m to about 5 0 ⁇ m Because the iron in the particles descnbed in this invention is not in the form of an iron oxide, as is
  • the lronxeramic particles are charactenzed by particles of iron and particles of ceramics bound together
  • the two components are maintained as individual entities
  • the charactenstic substructure of the particles formed dunng the process of joint deformation of the mechanical mixture of iron and ceramic powders also increases the magnetic susceptibility of iron inclusions m ferroceramic particles as compared with iron particles having other types of substructure
  • the adsorbed biologically active substance can compnse about 100% r 50% by weight, relative to the ceramic fraction of the particle, that being va ⁇ able from about 5% to 95% of the initial particle mass, ana most preferably from 15% to 60% In different terms, this can oe up to about 200 mg of adsorbed biologically active substance per gram of particles Therefore, in use, much less of the earner is injected to achieve a given dose of the biologically active substance or, alternatively, a higher dosage of the biologically active substance per injection is obtained than is the case with some previously known earners
  • the following descnbes a method for producing small quantities of the ferroceramic composition of this invention, it being understood that other means and mechanisms besides milling could be conceived of for jointly deforming iron and ceramic powders, which compnse the essential starting elements for production of the earner.
  • the procedure utilized exerts mechanical pressure on a mixture of ceramic and iron particles to deform the iron particles and develop a substantial substructure, which captures the ceramic
  • the formation of the ferroceramic particles is accomplished without the addition of heat in the process (although the mixture heats up dunng the mechanical deformation step), and is conducted m the presence of a liquid, for example ethanol, to inhibit oxidation of the iron and to assure that the particles produced are clean (stenle).
  • the liquid may also serve as a lubncant du ⁇ ng the milling ofthe iron and ceramic powder, and may reduce compacting of ceramic dunng processing. As a result, the density of the ceramic deposits m the composition is maintained so as to maximize adso ⁇ tion capacity ofthe particles
  • substantially pure iron particles having average diameters from 0 1 um to 5 ⁇ m in size are mixed with about 0 1 to 1 0 parts by weight of substantially pure ceramic granules (typically about 0 1 ⁇ to 5 0 ⁇ m in diameter)
  • substantially pure ceramic granules typically about 0 1 ⁇ to 5 0 ⁇ m in diameter
  • the iron particles and ceramic granules are mixed vigorously to achieve good distnbution throughout the volume
  • Each biologically active substance should be evaluated individually with the various types of ceramics in order to determine the optimum reversible ceramic binding.
  • Factors such as pH, temperature, particulate size, salts, solution viscosity and other potentially competing chemicals in solution can influence adso ⁇ tion capacity, rate, and deso ⁇ tion parameters.
  • the mixture is put into a standard laboratory planetary ball, or attrition mill of the type used in powder metallurgy.
  • the mill can have 6 mm diameter balls.
  • An appropriate amount of a liquid, for example ethanol, is added for lubrication.
  • the mixture is milled for between 1 and 12 hours, or for the time necessary to produce the particles heretofore described.
  • the speed of the mill may be anywhere in the range from about 100 ⁇ m to about 1000 ⁇ m (typically about 300 ⁇ m.
  • the particles are removed from the mill and separated from the grinding balls, for example, by a strainer.
  • the particles maybe resuspended in ethanol and homogenized to separate the particles from each other.
  • the ethanol is removed, for example, by rotary evaporation, followed by vacuum drying. Any suitable drying technique may be employed.
  • Particles should be handled so as to protect against oxidation of the iron, for example, in a nitrogen environment.
  • the particles should be collected according to appropriate size.
  • the particles may be passed through a 20 ⁇ m sieve and collected in an air cyclone to remove particles larger than 20 ⁇ m.
  • the cyclone only collects particles of a certain size and density, providing a method for removing fines and loose ceramic.
  • the sieved particles may be packaged under nitrogen and stored at room temperature.
  • Particles may be subaliquoted into dosage units, for example, between 50 and 500 mg per dose, and may be further overlayed with nitrogen, for example.
  • Dosage units may be sealed, for example, with butyl rubber stoppers and aluminum crimps.
  • Dosage units may then be sterilized by appropriate sterilization techniques, for example, gamma irradiation between 2.5 and 4.0 Mrads. Other sterilization techniques may also be used, for example, dry heat and electrobeam sterilization.
  • the carrier When ready for use, or before packaging if the carrier is to be prepared with a preselected biologically active substance already adsorbed thereon, about 50 mg to 150 mg (about 75 mg to about 100 mg is preferred to be absolutely assured of maximum adso ⁇ tion) of the biologically active substance in solution is added to 1 gram of the carrier.
  • the combination When ready for application to a patient, the combination is placed into suspension (for example, in 5 to 10 ml) of a biologically compatible liquid such as water or saline utilizing normal procedures.
  • a biologically compatible liquid such as water or saline
  • a composite particle composed of silica gel and iron was manufactured and preliminary characterization was performed. Characterization included particle sizing analysis (light scattering technique), surface area, pore size analysis, scanning electron microscopy and doxorubicin binding. Tests show that 95% of the final product has particles that are less than 1.11 m and have a mean (volume) diameter of 0.92 m. Results from surface area analysis show the iron-silica gel composite to have a total surface area of 48 m 2 /g and a total pore volume of 0.19 cc/g. SEM pictures reveal discrete particles made of both iron and silica gel components ( Figures 1 and 2). Preliminary doxorubicin binding assays ( Figure 4) show correlation between the concentration of bound (Q) and unbound (C) doxorubicin.
  • a composite particle composed of silica-C18 and iron was manufactured and preliminary characterization was performed. Characterization included particle sizing analysis (light scattering technique) and doxorubicin binding. Tests show that 95% of the final product has particles that are less than 1.60 m and have a mean (volume) diameter of 1.58 m. Preliminary doxorubicin binding assays ( Figure 5) show a linear correlation between the concentration of bound (Q) and unbound (C) doxorubicin.
  • Neoplastic agents may be especially useful with the particles of the invention. Examples of other useful neoplastic agents are exemplified in Table 2.
  • the adsorption capacities of hydroxyapatite panicles and the iron-hydroxyapatite composite particles were determined by a doxorubicin binding assay.
  • the Langmuir adsorption isotherms were determined from doxorubicin binding data at several concentrations and the total drug loading capacities were calculated from the inverse of the slope of the isotherms.
  • Figure 12 shows the isotherm for the iron-hydroxyapatite composite particles, which had a total capacity of 33 micrograms doxorubicm per milligram particles.
  • Figure 13 shows the isotherm for the hydroxyapatite alone, which has a binding capacity of 53 micrograms doxorubicin per milligram particles.
  • the difference in the drug binding capacity between the hydroxyapatite and the iron-hydroxyapatite composite material is due to the difference in compositions of these samples: the composite material of this example has ⁇ 25% per weight of hydroxyapatite.
  • Iron-hydroxyapatite composite particles were loaded with doxorubicin by soaking the particles in a concentrated aqueous solution of the drug.
  • the desorption profile was determined in a semi-dynamic assay by measuring the amount of doxorubicin released from the particles incubated in aliquots of human plasma at 37°C.
  • Figure 14 shows that the drug is effectively released from the microparticles as a function of time.
  • Iron-hydroxyapatite micro particles were incubated with Indium-I l l m PBS for 30min at 37° C and 1400rpm. The labeling efficiency was determined by comparing the amount of radioactivity in the incubation with the bound radioactivity after two washes with PBS. The inset in Figure 15 shows the resulting labeling efficiencies, which were approximately 60% after the second wash. The stability of the labeled particles was tested in both PBS and human plasma at 37°C. For each time point, the total activity of the sample was compared with the activity in the supernatant, After 12 days, the iron-hydroxyapatite micro particles in PBS retained more than 95% of the Indium-1 11 and the stability in of the particles in plasma was about 90%. These results demonstrated that the microparticles are easily labeled with Indium cation and that the labeling is very stable in human plasma.
  • Indium- 1 1 1-oxyquinoline complex was used in the incubation step after being prepared by well know methods. The efficiency and stability were determined as described previously and the results are shown in Figure 16. The labeling efficiency increased to over 90% after the second wash. The stability of the Indium-oxyquinoline labeled micro particles is very similar to the direct labeling, with more than 95% of the radioactivity remaining bound after 12 days in PBS and about 90% of the radioactivity still bound after 12 days in plasma. Thus, Indium complex can also be directly labeled in a very stable manner onto the particles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Paints Or Removers (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention se rapporte à des compositions à sensibilité magnétique comportant des particules fer-céramique utilisées pour transporter des substances destinées à des fins de diagnostic médical in vivo et/ou de traitement. Ces particules sont formées par déformation conjointe de fer et de poudre céramique. Des substances utilisables à des fins diagnostiques ou thérapeutiques peuvent être adsorbées sur ces particules. Ces particules peuvent être produites par broyage mécanique d'un mélange de poudres céramiques et de fer.
EP00972209A 1999-10-18 2000-10-13 Porteurs magnetiques cibles composes de fer et de matieres poreuses pour l'administration ciblee d'agents biologiquement actifs Withdrawn EP1221974A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16029399P 1999-10-18 1999-10-18
US160293P 1999-10-18
PCT/US2000/028615 WO2001028587A2 (fr) 1999-10-18 2000-10-13 Porteurs magnetiques cibles composes de fer et de matieres poreuses pour l'administration ciblee d'agents biologiquement actifs

Publications (1)

Publication Number Publication Date
EP1221974A2 true EP1221974A2 (fr) 2002-07-17

Family

ID=22576298

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00972209A Withdrawn EP1221974A2 (fr) 1999-10-18 2000-10-13 Porteurs magnetiques cibles composes de fer et de matieres poreuses pour l'administration ciblee d'agents biologiquement actifs

Country Status (15)

Country Link
EP (1) EP1221974A2 (fr)
JP (3) JP2003512336A (fr)
KR (1) KR20020064299A (fr)
CN (1) CN1287859C (fr)
AU (1) AU772755B2 (fr)
BR (1) BR0014877A (fr)
CA (1) CA2387925A1 (fr)
CZ (1) CZ293919B6 (fr)
DE (1) DE1221974T1 (fr)
ES (1) ES2182731T1 (fr)
HK (1) HK1045110A1 (fr)
IL (1) IL149004A0 (fr)
MX (1) MXPA02003891A (fr)
NZ (1) NZ518311A (fr)
WO (1) WO2001028587A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
EP1668424A4 (fr) * 2003-09-12 2009-11-25 Onkor Pharmaceuticals Inc Particules ciblables magnetiquement contenant des composes magnetiques et des polymeres biocompatibles pour l'administration specifique de sites d'agents actifs biologiquement
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
JP4982084B2 (ja) * 2004-02-09 2012-07-25 株式会社サンギ 抗腫瘍剤
GB0403856D0 (en) * 2004-02-20 2004-03-24 Algeta As Composition
EP1735013B1 (fr) * 2004-02-20 2012-02-08 Algeta ASA Particules d'hydroxyapatite emettrices de rayons alpha et beta
JP2006199810A (ja) * 2005-01-20 2006-08-03 Yokohama National Univ 複合粒子およびその製造方法
EP1872798B1 (fr) * 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Agent anti-tumeur absorbable par l intestin
EP2427179A4 (fr) 2009-05-04 2013-09-11 Psivida Inc Particules de silicium poreux d'élution de médicament
CA2816576C (fr) * 2010-11-01 2020-06-02 Psivida Us, Inc. Dispositifs a base de silicium pouvant etre biologiquement erodes pour administration d'agents therapeutiques
CN104583397B (zh) * 2012-08-28 2018-05-25 生物立方体系统有限公司 用于从生物样品迅速分离核酸扩增反应用生物分子的多孔性固体相及其用途
EP2968571A4 (fr) 2013-03-15 2016-09-07 Psivida Inc Compositions à base de silicium bioérodables pour l'administration d'agents thérapeutiques
JP6443907B2 (ja) * 2014-02-17 2018-12-26 浩文 山本 造影剤の腫瘍への集積を促進するための集積促進剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243652A (en) * 1978-07-14 1981-01-06 The Procter & Gamble Company Gastrointestinal scanning agent
DE68920778T2 (de) * 1988-05-24 1995-05-18 Anagen Uk Ltd Magnetisch anziehbare Teilchen und Herstellungsverfahren.
EP0772776B1 (fr) * 1994-07-27 2000-03-22 Herbert Dr. Pilgrimm Particules superparamagnetiques, leur procede de production et leur utilisation
WO1997001304A1 (fr) * 1995-06-29 1997-01-16 Mallinckrodt Medical, Inc. Particules d'apatite radiomarquees contenant un ion paramagnetique
JP3735990B2 (ja) * 1997-01-28 2006-01-18 東ソー株式会社 磁性シリカゲルの製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0128587A2 *

Also Published As

Publication number Publication date
WO2001028587A3 (fr) 2002-01-03
KR20020064299A (ko) 2002-08-07
AU1090501A (en) 2001-04-30
JP2003321348A (ja) 2003-11-11
CZ293919B6 (cs) 2004-08-18
CN1420787A (zh) 2003-05-28
IL149004A0 (en) 2002-11-10
CN1287859C (zh) 2006-12-06
DE1221974T1 (de) 2003-02-06
NZ518311A (en) 2003-10-31
JP2005200426A (ja) 2005-07-28
MXPA02003891A (es) 2002-12-09
AU772755B2 (en) 2004-05-06
BR0014877A (pt) 2002-06-11
WO2001028587A2 (fr) 2001-04-26
ES2182731T1 (es) 2003-03-16
CZ20021357A3 (cs) 2002-11-13
HK1045110A1 (zh) 2002-11-15
CA2387925A1 (fr) 2001-04-26
JP2003512336A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
US6482436B1 (en) Magnetically responsive composition
AU744205B2 (en) Magnetically responsive composition
EP0683665B1 (fr) Composition a sensibilite magnetique servant a transporter des substances a activite biologique et procedes de production et d'utilisation
US20060204442A1 (en) Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
Ghosal et al. A detailed review on synthesis, functionalization, application, challenges, and current status of magnetic nanoparticles in the field of drug delivery and gene delivery system
AU772755B2 (en) Magnetic targeted carrier composed of iron and porous materials for the targeted delivery of biologically active agents
JP5526156B2 (ja) 磁性粒子、及びその製造方法、並びに磁性粒子含有製剤
US20030120355A1 (en) Biocompatible and biodegradable polymers for diagnostic and therapeutic radioisotope delivery
US20040136905A1 (en) Magnetically guided particles for radiative therapies
Johnson et al. The MTC technology: a platform technology for the site-specific delivery of pharmaceutical agents
Chang et al. Conjugation of monodisperse chitosan-bound magnetic nanocarrier with epirubicin for targeted cancer therapy
US20070274907A1 (en) Magnetically Targetable Mitomycin C Compositions and Methods of Their Use
Guo et al. Efficient conjugation doxorubicin to bacterial magnetic nanoparticles via a triplex hands coupling reagent
RU97103863A (ru) Магнитоуправляемое противоопухолевое средство, способ его получения, способ получения суспензии магнитоуправляемого лекарственного средства, способ лечения, противоопухолевое, антиметастатическое, химиотерапевтическое, лучевое, гемо- и иммуностимулирующее и эмболизирующее средство
WO2003059325A1 (fr) Compositions a administration par voie magnetique
MXPA00006625A (en) Magnetically responsive composition
HK1013256B (en) Magnetically responsive composition for carrying biologically active substances and methods of production and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020416

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FERX INCORPORATED

REG Reference to a national code

Ref country code: GR

Ref legal event code: PP

Ref document number: 20020300054

Country of ref document: GR

EL Fr: translation of claims filed
TCAT At: translation of patent claims filed
TCNL Nl: translation of patent claims filed
DET De: translation of patent claims
17Q First examination report despatched

Effective date: 20040319

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ONKOR PHARMACEUTICALS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20091230BHEP

Ipc: A61P 35/00 20060101ALI20091230BHEP

Ipc: A61K 9/50 20060101ALI20091230BHEP

Ipc: A61K 41/00 20060101AFI20091230BHEP

RTI1 Title (correction)

Free format text: MAGNETIC TARGETED CARRIER FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1045110

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100504